Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRD5A1 | P18405 | 1/20 | 0.37 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.37 |
| ▸ | CTSC | P53634 | 1/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.35 |
| ▸ | RET | P07949 | 3/20 | 0.35 |
| ▸ | LMNA | P02545 | 3/20 | 0.35 |
| ▸ | RAB9A | P51151 | 3/20 | 0.35 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.35 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.35 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.35 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.35 |
| ▸ | HTR1A | P08908 | 2/20 | 0.35 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.35 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.35 |
| ▸ | DRD2 | P14416 | 2/20 | 0.35 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1918556 | 1.00 | SRD5A1 (0.37) | SRD5A1SRD5A2CTSCSLC6A2CYP3A4 | |
| SCHEMBL4364540 | 1.00 | SRD5A1 (0.37) | SRD5A1SRD5A2CTSCSLC6A2CYP3A4 | |
| SCHEMBL1917996 | 0.86 | LMNA (0.35) | SRD5A1SRD5A2CTSCSLC6A2CYP3A4 | |
| SCHEMBL1918496 | 0.86 | LMNA (0.35) | SRD5A1SRD5A2CTSCSLC6A2CYP3A4 | |
| SCHEMBL1918498 | 0.86 | LMNA (0.35) | SRD5A1SRD5A2CTSCSLC6A2CYP3A4 | |
| SCHEMBL1917993 | 0.86 | LMNA (0.35) | SRD5A1SRD5A2CTSCSLC6A2CYP3A4 | |
| SCHEMBL1917028 | 0.83 | HTR2B (0.42) | SLC6A2CYP1A2LMNACHRM2CHRM4 | |
| SCHEMBL1917023 | 0.83 | HTR2B (0.42) | SLC6A2CYP1A2LMNACHRM2CHRM4 | |
| SCHEMBL1918280 | 0.83 | HTR2B (0.42) | SLC6A2CYP1A2LMNACHRM2CHRM4 | |
| SCHEMBL16064651 | 0.82 | SRD5A1 (0.51) | SRD5A1SRD5A2RAB9ATP53NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3081213-B1 | TRICYCLIC COMPOUND | KYOWA KIRIN CO LTD (JP) | 2020-04-01 | — | — | EP | disclosed |
| US-9475805-B2 | Tricyclic compound | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2016-10-25 | — | — | US | disclosed |
| EP-3081213-A1 | TRICYCLIC COMPOUND | Kyowa Hakko Kirin Co., Ltd. (JP) | 2016-10-19 | — | — | EP | disclosed |
| US-20150291587-A1 | TRICYCLIC COMPOUND | KYOWA KIRIN CO., LTD. (JP) | 2015-10-15 | — | — | US | disclosed |
| EP-1988091-B1 | TRICYCLIC COMPOUNDS | KYOWA HAKKO KIRIN CO LTD (JP) | 2015-06-10 | — | — | EP | disclosed |
| US-20130267711-A1 | TRICYCLIC COMPOUND | KYOWA HAKKO KIRIN CO LTD (JP) | 2013-10-10 | — | — | US | disclosed |
| US-8486980-B2 | Tricyclic compound | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2013-07-16 | — | — | US | disclosed |
| US-8242151-B2 | Tricyclic compounds | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2012-08-14 | — | — | US | disclosed |
| US-20110201640-A1 | TRICYCLIC COMPOUND | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2011-08-18 | — | — | US | disclosed |
| EP-2327690-A1 | TRICYCLIC COMPOUND | Kyowa Hakko Kirin Co., Ltd. (JP) | 2011-06-01 | — | — | EP | disclosed |
| US-20090176760-A1 | TRICYCLIC COMPOUNDS | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2009-07-09 | — | — | US | disclosed |
| EP-1988091-A1 | TRICYCLIC COMPOUNDS | Kyowa Hakko Kogyo Co., Ltd (JP) | 2008-11-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150291587-A1 | TRICYCLIC COMPOUND | PPARA, PPARG, PPARD | SRD5A1 1120/4885SRD5A2 1433/4885CTSC 472/4885 |
| US-20130267711-A1 | TRICYCLIC COMPOUND | PPARA, PPARG, PPARD | SRD5A1 1120/4885SRD5A2 1433/4885CTSC 472/4885 |
| US-20110201640-A1 | TRICYCLIC COMPOUND | PPARG, PPARA, PPARD | SRD5A1 767/4885SRD5A2 898/4885CTSC 864/4885 |
| US-20090176760-A1 | TRICYCLIC COMPOUNDS | PPARG, PPARD, PPARA | SRD5A1 816/4885SRD5A2 737/4885CTSC 1436/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.